肺癌辅助治疗中的铁死亡——选定植物药物和分离代谢物的潜力。
Ferroptosis in the adjuvant treatment of lung cancer-the potential of selected botanical drugs and isolated metabolites.
发表日期：2024
作者：
Xiaoyan Tian, Kunling Fu, Xuemin Huang, Haiyan Zou, Nianmei Shi, Jiayang Li, Yuxiang Bao, Sisi He, Junyuan Lv
来源：
Frontiers in Pharmacology
摘要：
铁死亡代表一种独特的细胞死亡形式，与坏死、自噬、细胞凋亡或焦亡无关。其特征是细胞内铁依赖性脂质过氧化。目前的文献表明，许多植物药物和分离的代谢物可以调节铁死亡，从而对肺癌细胞或动物模型产生抑制作用。本综述的目的是阐明植物药物和分离代谢物在肺癌背景下调节铁死亡的机制，从而为肺癌治疗提供潜在的见解。必须强调的是，这些临床前研究结果不应被解释为这些治疗方法可以立即转化为临床应用的证据。未来，我们将继续研究这些药物的药理学、药代动力学和毒理学，并在临床试验中评价其疗效和安全性，旨在为肺癌治疗新药的开发提供新途径。 .版权所有 © 2024 田、付、黄、邹、石、李、包、何、吕。
Ferroptosis represents a distinct form of cell death that is not associated with necrosis, autophagy, apoptosis, or pyroptosis. It is characterised by intracellular iron-dependent lipid peroxidation. The current literature indicates that a number of botanical drugs and isolated metabolites can modulate ferroptosis, thereby exerting inhibitory effects on lung cancer cells or animal models. The aim of this review is to elucidate the mechanisms through which botanical drugs and isolated metabolites regulate ferroptosis in the context of lung cancer, thereby providing potential insights into lung cancer treatment. It is crucial to highlight that these preclinical findings should not be interpreted as evidence that these treatments can be immediately translated into clinical applications. In the future, we will continue to study the pharmacology, pharmacokinetics and toxicology of these drugs, as well as evaluating their efficacy and safety in clinical trials, with the aim of providing new approaches to the development of new agents for the treatment of lung cancer.Copyright © 2024 Tian, Fu, Huang, Zou, Shi, Li, Bao, He and Lv.